Report Detail
Global Kidney Fibrosis Treatment Market Size, Status and Forecast 2019-2025
- RnM2683560 |
- 21 May, 2020 |
- Global |
- 90 Pages |
- QYResearch |
- Other
This report covers market size and forecasts of Kidney Fibrosis Treatment, including the following market information:
Global Kidney Fibrosis Treatment Market Size, 2019-2021, and 2020 (quarterly data), (US$ Million)
Global Kidney Fibrosis Treatment Market Size by Type and by Application, 2019-2021, and 2020 (quarterly data), (US$ Million)
Global Kidney Fibrosis Treatment Market Size by Region (and Key Countries), 2019-2021, and 2020 (quarterly data), (US$ Million)
Global Kidney Fibrosis Treatment Market Size by Company, 2019- 2020 (quarterly data), (US$ Million)
Key market players
Major competitors identified in this market include Merck and Co(US), Pfizer Inc(US), F. Hoffman-La Roche(Switzerland), InterMune Inc(US), Galectin Therapeutics(US), La Jolla Pharmaceutical Company(US), ProMetic Life-Sciences Inc(Canada), BioLine Rx(Israel), Genzyme Corporation(US), etc.
Based on the Region:
Asia-Pacific (China, Japan, South Korea, India and ASEAN)
North America (US and Canada)
Europe (Germany, France, UK and Italy)
Rest of World (Latin America, Middle East & Africa)
Based on the Type:
Angiotensin Converting Enzyme (ACE) Inhibitors
Pirfenidone
Renin Inhibitors
Angiotensin II Receptor Blockers (ARBs)
Vasopeptidase Inhibitors
Based on the Application:
Chronic Kidney Diseases
Kidney Cancer Treatment
Others
- 1.4.1 Research Process
- 1.4.2 Data Triangulation
- 1.4.3 Research Approach
- 1.4.4 Base Year
- 1.5.1 Covid-19 Impact: Global GDP Growth, 2019, 2020 and 2021 Projections
- 1.5.2 Covid-19 Impact: Commodity Prices Indices
- 1.5.3 Covid-19 Impact: Global Major Government Policy
2 Global Kidney Fibrosis Treatment Quarterly Market Size Analysis
- 2.1 Kidney Fibrosis Treatment Business Impact Assessment - COVID-19
- 2.1.1 Global Kidney Fibrosis Treatment Market Size, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026
- 2.2 Global Kidney Fibrosis Treatment Quarterly Market Size 2020-2021
- 2.3 COVID-19-Driven Market Dynamics and Factor Analysis
- 2.3.1 Drivers
- 2.3.2 Restraints
- 2.3.3 Opportunities
- 2.3.4 Challenges
3 Quarterly Competitive Assessment, 2020
- 3.1 By Players, Global Kidney Fibrosis Treatment Quarterly Market Size, 2019 VS 2020
- 3.2 By Players, Kidney Fibrosis Treatment Headquarters and Area Served
- 3.3 Date of Key Players Enter into Kidney Fibrosis Treatment Market
- 3.4 Key Players Kidney Fibrosis Treatment Product Offered
- 3.5 Mergers & Acquisitions, Expansion Plans
4 Impact of Covid-19 on Kidney Fibrosis Treatment Segments, By Type
- 4.1 Introduction
- 1.4.1 Angiotensin Converting Enzyme (ACE) Inhibitors
- 1.4.2 Pirfenidone
- 1.4.3 Renin Inhibitors
- 1.4.4 Angiotensin II Receptor Blockers (ARBs)
- 1.4.5 Vasopeptidase Inhibitors
- 4.2 By Type, Global Kidney Fibrosis Treatment Market Size, 2019-2021
5 Impact of Covid-19 on Kidney Fibrosis Treatment Segments, By Application
- 5.1 Overview
- 5.5.1 Chronic Kidney Diseases
- 5.5.2 Kidney Cancer Treatment
- 5.5.3 Others
- 5.2 By Application, Global Kidney Fibrosis Treatment Market Size, 2019-2021
- 5.2.1 By Application, Global Kidney Fibrosis Treatment Market Size by Application, 2019-2021
6 Geographic Analysis
- 6.1 Introduction
- 6.2 North America
- 6.2.1 Macroeconomic Indicators of US
- 6.2.2 US
- 6.2.3 Canada
- 6.3 Europe
- 6.3.1 Macroeconomic Indicators of Europe
- 6.3.2 Germany
- 6.3.3 France
- 6.3.4 UK
- 6.3.5 Italy
- 6.4 Asia-Pacific
- 6.4.1 Macroeconomic Indicators of Asia-Pacific
- 6.4.2 China
- 6.4.3 Japan
- 6.4.4 South Korea
- 6.4.5 India
- 6.4.6 ASEAN
- 6.5 Rest of World
- 6.5.1 Latin America
- 6.5.2 Middle East and Africa
7 Company Profiles
- 7.1 Merck and Co(US)
- 7.1.1 Merck and Co(US) Business Overview
- 7.1.2 Merck and Co(US) Kidney Fibrosis Treatment Quarterly Revenue, 2020
- 7.1.3 Merck and Co(US) Kidney Fibrosis Treatment Product Introduction
- 7.1.4 Merck and Co(US) Response to COVID-19 and Related Developments
- 7.2 Pfizer Inc(US)
- 7.2.1 Pfizer Inc(US) Business Overview
- 7.2.2 Pfizer Inc(US) Kidney Fibrosis Treatment Quarterly Revenue, 2020
- 7.2.3 Pfizer Inc(US) Kidney Fibrosis Treatment Product Introduction
- 7.2.4 Pfizer Inc(US) Response to COVID-19 and Related Developments
- 7.3 F. Hoffman-La Roche(Switzerland)
- 7.3.1 F. Hoffman-La Roche(Switzerland) Business Overview
- 7.3.2 F. Hoffman-La Roche(Switzerland) Kidney Fibrosis Treatment Quarterly Revenue, 2020
- 7.3.3 F. Hoffman-La Roche(Switzerland) Kidney Fibrosis Treatment Product Introduction
- 7.3.4 F. Hoffman-La Roche(Switzerland) Response to COVID-19 and Related Developments
- 7.4 InterMune Inc(US)
- 7.4.1 InterMune Inc(US) Business Overview
- 7.4.2 InterMune Inc(US) Kidney Fibrosis Treatment Quarterly Revenue, 2020
- 7.4.3 InterMune Inc(US) Kidney Fibrosis Treatment Product Introduction
- 7.4.4 InterMune Inc(US) Response to COVID-19 and Related Developments
- 7.5 Galectin Therapeutics(US)
- 7.5.1 Galectin Therapeutics(US) Business Overview
- 7.5.2 Galectin Therapeutics(US) Kidney Fibrosis Treatment Quarterly Revenue, 2020
- 7.5.3 Galectin Therapeutics(US) Kidney Fibrosis Treatment Product Introduction
- 7.5.4 Galectin Therapeutics(US) Response to COVID-19 and Related Developments
- 7.6 La Jolla Pharmaceutical Company(US)
- 7.6.1 La Jolla Pharmaceutical Company(US) Business Overview
- 7.6.2 La Jolla Pharmaceutical Company(US) Kidney Fibrosis Treatment Quarterly Revenue, 2020
- 7.6.3 La Jolla Pharmaceutical Company(US) Kidney Fibrosis Treatment Product Introduction
- 7.6.4 La Jolla Pharmaceutical Company(US) Response to COVID-19 and Related Developments
- 7.7 ProMetic Life-Sciences Inc(Canada)
- 7.7.1 ProMetic Life-Sciences Inc(Canada) Business Overview
- 7.7.2 ProMetic Life-Sciences Inc(Canada) Kidney Fibrosis Treatment Quarterly Revenue, 2020
- 7.7.3 ProMetic Life-Sciences Inc(Canada) Kidney Fibrosis Treatment Product Introduction
- 7.7.4 ProMetic Life-Sciences Inc(Canada) Response to COVID-19 and Related Developments
- 7.8 BioLine Rx(Israel)
- 7.8.1 BioLine Rx(Israel) Business Overview
- 7.8.2 BioLine Rx(Israel) Kidney Fibrosis Treatment Quarterly Revenue, 2020
- 7.8.3 BioLine Rx(Israel) Kidney Fibrosis Treatment Product Introduction
- 7.8.4 BioLine Rx(Israel) Response to COVID-19 and Related Developments
- 7.9 Genzyme Corporation(US)
- 7.9.1 Genzyme Corporation(US) Business Overview
- 7.9.2 Genzyme Corporation(US) Kidney Fibrosis Treatment Quarterly Revenue, 2020
- 7.9.3 Genzyme Corporation(US) Kidney Fibrosis Treatment Product Introduction
- 7.9.4 Genzyme Corporation(US) Response to COVID-19 and Related Developments
8 Key Findings
9 Appendix
- 9.1 About US
Summary:
Get latest Market Research Reports on Kidney Fibrosis Treatment . Industry analysis & Market Report on Kidney Fibrosis Treatment is a syndicated market report, published as Global Kidney Fibrosis Treatment Market Size, Status and Forecast 2019-2025. It is complete Research Study and Industry Analysis of Kidney Fibrosis Treatment market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
